Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel
Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel
复制标题
DOI：
10.1016/j.urology.2011.07.1416
复制
发表时间：
2011-11-01
期刊：
影响因子：
2.1
通讯作者：
Fukui, Iwao
中科院分区：
文献类型：
--
作者：
Ito, Masaya;Saito, Kazutaka;Fukui, Iwao
目的验证C反应蛋白（CRP）对单机构接受多西他赛治疗的去势抵抗性前列腺癌（CRPC）患者预后的影响。方法选取2005年1月至2010年5月在本机构接受多西他赛治疗的连续80例CRPC患者为一组，每3周静脉注射多西他赛75 mg/m(2)。使用 Cox 比例风险模型评估所有协变量（包括 CRP）的预后价值。根据多变量分析的结果描述了总体生存的风险分层。结果所有患者的中位生存期为14.5个月。多变量分析显示CRP和血红蛋白水平是总体生存的独立预后因素。根据 CRP 浓度升高和/或血红蛋白水平低的情况，所有患者被分为 3 个风险组：没有危险因素的患者（低风险组）、有 1 个危险因素的患者（中风险组）和有 2 个危险因素的患者（高风险组）。总生存曲线根据风险组明显分层，低、中、高风险组的1年总生存率分别为86.3%、60.5%和23.0%（P<0.001）。结论CRP是多西紫杉醇治疗CRPC患者总生存的独立预后因素。基于 CRP 和血红蛋白的风险分层可能有助于估计总体生存率。泌尿学 78:1131-1135, 2011。(C) 2011 Elsevier Inc.
OBJECTIVE To verify the prognostic impact of C-reactive protein (CRP) for patients with castration-resistant prostate cancer (CRPC) treated with docetaxel in a single institution.METHODS A group of 80 consecutive patients with CRPC were treated with docetaxel in our institution from January 2005 to May 2010. The patients received 75 mg/m(2) of docetaxel intravenously every 3 weeks. The prognostic value of all covariables, including CRP, was assessed using the Cox proportional hazard model. Risk stratification for overall survival was described from the results of the multivariable analysis.RESULTS The median survival period for all patients was 14.5 months. The multivariable analysis showed that CRP and hemoglobin levels were independent prognostic factors for overall survival. Based on the presence of an elevated CRP concentration and/or a low hemoglobin level, all patients were stratified into 3 risk groups: those with no risk factors (low-risk group), those with 1 risk factor (intermediate-risk group), and those with 2 risk factors (high-risk group). The overall survival curves were clearly tiered according to the risk groups, with the 1-year overall survival rates being 86.3%, 60.5%, and 23.0% for the low-, intermediate-, and high-risk groups, respectively (P < .001).CONCLUSION CRP is an independent prognostic factor for overall survival of patients with CRPC treated with docetaxel. Risk stratification based on CRP and hemoglobin could be helpful for estimating the overall survival. UROLOGY 78:1131-1135, 2011. (C) 2011 Elsevier Inc.